News: Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

10.26USD
17 Apr 2015
Change (% chg)

$-0.29 (-2.75%)
Prev Close
$10.55
Open
$10.45
Day's High
$10.50
Day's Low
$10.13
Volume
1,497,833
Avg. Vol
4,752,085
52-wk High
$16.87
52-wk Low
$2.45

Search Stocks
Select another date:

Mon, Feb 9 2015

US STOCKS-Wall St down on China, Greek worry; energy gains

* Indexes down: Dow 0.28 pct, S&P 0.12 pct, Nasdaq 0.02 pct (Updates to afternoon trade, commentary)

Promising data bodes well for all-Achillion hep C treatment

- Achillion Pharmaceuticals Inc's experimental hepatitis C drug, when used with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus in six weeks, the shortest duration and highest response achieved by any two-drug treatment.

UPDATE 2-Promising data bodes well for all-Achillion hep C treatment

* Study shows Achillion's inhibitor looks best-in-class: analyst

US STOCKS-Wall St dips on China, Greek worry; energy gains

* Indexes off: Dow 0.33 pct, S&P 0.18 pct, Nasdaq 0.24 pct (Updates to late morning trade)

US STOCKS-Wall St dips after China data; Greek worry continues

* Qualcomm near deal with China on antitrust dispute, shares climb

US STOCKS-Wall St to open lower on China data, Greek worry

* Futures off: Dow 105 pts, S&P 12 pts, Nasdaq 24 pts (Adds quote, updates prices)

Achillion data shows promise of shorter-duration hep C treatment

- Data from Achillion Pharmaceuticals Inc's hepatitis C drug trials showed the company could develop a shorter-duration treatment rivaling offerings from Gilead Sciences Inc and Abbvie Inc.

UPDATE 1-Achillion data shows promise of shorter-duration hep C treatment

* Achillion's NS5A inhibitor superior to Gilead's - analysts

Achillion shares soar as potential treatment seen as hep C cure

Dec 22 - Achillion Pharmaceuticals Inc said it would test a combination of two of its experimental hepatitis C drugs after they showed promise against the virus in separate studies.

Select another date:
Search Stocks